Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis
Authors:
- Michela BuglioneMBMichela Buglione
- Sara PedrettiSPSara Pedretti
- Stefano GipponiSGStefano Gipponi
- Alice TodeschiniATAlice Todeschini
- Ludovica PegurriLPLudovica Pegurri
- Loredana CostaLCLoredana Costa
- Laura DonadoniLDLaura Donadoni
- Salvatore GrisantiSGSalvatore Grisanti
- Marco FontanellaMFMarco Fontanella
- Roberto LiserreRLRoberto Liserre
- Fabio FacchettiFFFabio Facchetti
- Alessandro PadovaniAPAlessandro Padovani
- 3 December 2013
- journal article
- radiotherapy
- Published by Springer Nature in La radiologia medica
- Vol. 119 (6) , 432-439
Abstract
Purpose The treatment of low-grade glioma is still debated. Surgery is the first-line approach, and the correct timing of radiation therapy has not yet been defined since “early” radiation therapy improves relapse-free survival but not overall survival. Since a longer progression-free survival is desirable, the main issue related to radiotherapy is the incidence of late neurocognitive toxicity. Materials and methods Ninety-five patients with low-grade glioma were consecutively treated with early (within 3 months) or late (at disease progression) post-surgical radiation therapy. Clinical and therapeutic factors were entered into the analysis overall (OS) and progression-free (PFS) survival, and the distribution in two accrual periods identified based on the evolution of imaging procedures and radiotherapy techniques were compared. For 6/18 long survivors (LS) without evidence of disease, neurocognitive evaluation was obtained and the dose to the hippocampus region was retrospectively calculated. Results Univariate analysis of OS showed a statistically significant advantage for grade 1 and oligodendroglioma histology, better performance status [Karnofsky index (KI)], age <40 years, radical surgery, no steroid treatment; PFS was significantly related with younger age, better KI and “early” radiotherapy. Multivariate analysis of OS confirmed the significance of all variables except surgery; for PFS, only “early” radiotherapy and better KI retained significance. Memory impairment was evident in 4/6 of the LS tested; quality of life was good and executive functions were normal. Conclusion Radiotherapy remains an essential component in the treatment of low-grade glioma. Prospective studies are needed to evaluate the relative contributions of the disease itself and of surgery, radiation and chemotherapy to long-term neurocognitive damage.Keywords
This publication has 46 references indexed in Scilit:
- Radiation Associated Brainstem InjuryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Radiation Dose–Volume Effects in the BrainInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Biologie des gliomes cérébrauxCancer/Radiothérapie, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- First‐line nitrosourea‐based chemotherapy in symptomatic non‐resectable supratentorial pure low‐grade astrocytomasEuropean Journal of Neurology, 2005
- PCV Chemotherapy for Recurrent Oligodendrogliomas and OligoastrocytomasNeurosurgery, 1998
- Construct validity in the trail making test: What makes part B harder?Journal of Clinical and Experimental Neuropsychology, 1995
- The Neuropsychiatric InventoryNeurology, 1994
- Cognitive functions and quality of life in patients with low‐grade gliomas: The impact of radiotherapyAnnals of Neurology, 1994
- Relationships between Parts A and B of the Trail Making TestJournal of Clinical Psychology, 1987